CoChat

Evolution of the Food and Drug Administration Approach to Liver Safety Assessment for New Drugs: Current Status and Challenges

Open access
Senior, John R. · 2014 · Drug Safety
Cited by 122

The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.

Abstract

Prompted by approval in 1997 of troglitazone and bromfenac, two drugs that promptly began to show serious and sometimes fatal liver toxicity, we began at the Food and Drug Administration (FDA) a series of annual conferences in 1999 to consider issues of drug-induced liver injury (DILI). First inviting reviewers of new drug applications we opened the audiences in 2001 to pharmaceutical industry and academic consultants to industry and FDA, and slides shown at the meetings were posted on the internet to be available at the website of the American Association for the Study of Liver Diseases (AASLD)-go to ( http://www.aasld.org/dili/Pages/default.aspx ). Observations by Dr. Hyman J. Zimmerman that "drug-induced hepatocellular jaundice is a serious lesion" with possible mortality formed a basis for developing a computer program to plot peak serum values for alanine aminotransferase (ALT) and total bilirubin (TBL) in an x-y log-log graph for all subjects enrolled in clinical trials. This program had the capability to show the time course of all liver tests for individuals who had both hepatocellular injury and reduced whole liver function, plus clinical narratives to diagnose the severity and most likely cause of the abnormalities. We called the program eDISH (for evaluation of Drug-Induced Serious Hepatotoxicity), and began in 2004 to use it to assess DILI in clinical trial subjects. From 2008, comments made by the presenters at the conferences about their slides and ensuing discussions have been added to the website. All this has raised awareness of the problem, and since 1997, the FDA has not had to withdraw a single drug because of post-marketing hepatotoxicity. Many issues still remain to be resolved; among the most controversial is the best method to estimate likelihood that a given liver injury was actually caused by the drug in question. On November 9, 2012, a workshop was convened to discuss the best practices for the assessment of drug-induced liver injury (DILI) in clinical trials.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1007/s40264-014-0182-7

Cites

3 of 3 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 3 references

Research works printed but not linked: 24

  1. Editorial (no authors listed). Withdrawals of FDA-approved drugs raise questions. Mayo Clin Health Lett. 1998; 16(11):4.
  2. Vidt DG, Speerhas RA, Reddy SS. Troglitazone: a new antihyperglycemic agent. Cleve Clin J Med. 1997;64(5):238–40. · doi:10.3949/ccjm.64.5.238
  3. Notice (no authors listed). Bromfenac marketed for short-term-pain relief. Am J Health Syst Pharm. 1997;54(19):2151–2. · doi:10.1093/ajhp/54.19.2151
  4. Watkins PB, Whitcomb RW. Hepatic dysfunction associated with troglitazone. N Engl J Med. 1998;338(13):916–7. · DOI · Paper page
  5. Moses PI, Schroeder B, Alkhatib O, Ferrentino N, Suppan T, Lidosfsky SD. Severe hepato-toxicity associated with bromfenac sodium. Am J. Gastroenterol. 1999;84(5):1393–6. · doi:10.1111/j.1572-0241.1999.01093.x
  6. Wise J. Diabetes drug withdrawn (in Britain) after reports of hepatic events. BMJ. 1997;315(7122):1564. · DOI
  7. Notice (no authors listed). Troglitazone withdrawn from market. Am J Health Syst Pharm. 2000; 57(9):834. · doi:10.1093/ajhp/57.9.834b
  8. Friedman MA, Woodcock J, Lumpkin MM, Shuren JE, Hass AE, Thompson LJ. The safety of newly approved medicines: do recent market removals mean there is a problem? JAMA. 1999;281(18):1728–34. · DOI · Paper page
  9. Szarfman A, Machado SG, O’Neill RT. Use of screening algorithms and computer systems to efficiently signal high-than-expected combinations of drugs and events in the US FDAs spontaneous reports database. Drug Saf. 2002;25(6):381–92. · DOI · Paper page
  10. Reuben A. Hy’s Law. Hepatology. 2004;39(2):574–8. · DOI · Paper page
  11. Zimmerman HJ. The spectrum of hepatotoxicity. (Kober Lecture 1968). Perspect Biol Med. 1968;12(1):135–61. · DOI · Paper page
  12. Popper H, Schaffner F. Drug-induced hepatic injury. Ann Intern Med. 1959;51:1230–53. · doi:10.7326/0003-4819-51-6-1230
  13. Davidson CS, Leevy CM, Chamberlayne EC, editors. Guidelines for Detection of Hepatotoxicity due to Drugs and Chemicals. [Fogarty Conference, 1978] NIH Publication No. 79-313. Washington, DC: US Government Printing Office; 1979. p. 109.
  14. Watkins PB, Desai M, Berkowitz SD, Peters G, Horsmans Y, Larrey D, Maddrey W. Evaluation of drug-induced serious hepatotoxicity (eDISH): application of this data organization approach to phase III clinical trials of rivaroxaban after total hip or knee replacement surgery. Drug Saf. 2011;34(3):243–52. · DOI
  15. Senior JR. Alanine aminotransferase: a clinical and regulatory tool for detecting liver injury—past, present, and future. Clin Pharmacol Ther. 2012;2(3):332–9. · DOI · Paper page
  16. Ledley RS, Lusted RB. Reasoning foundations of medical diagnosis: symbolic logic, probability and value theory aid our understanding of how physicians reason. Science. 1959;130(3366):9–21. · DOI · Paper page
  17. Qureshi ZP, Seoane-Vasquez E, Rodriguez-Monguio R, Stevenson KB, Szeinbach SL. Market withdrawal of new molecular entities approved in the United States from 1980 to 2009. Pharmacoepidemiol Drug Saf. 2011;20(7):772–7. · DOI · Paper page
  18. Chen HJL, Bloch KJ, Maclean JA. Acute eosinophilic hepatitis from trovafloxacin. [Letter]. N Engl J Med. 2000;342(5):359–60. · DOI
  19. Lucena MI, Andrade RJ, Rodrigo L, Salmeron J, Alvarez A, Lopez-Garrido MJ, Camargo R, Alcantara R. Trovafloxacin-induced acute hepatitis. [Letter]. Clin Infect Dis. 2000;30(2):400–1. · DOI · Paper page
  20. Rockey DC, Seeff LB, Rochon J, Freston J, Chalsani N, Bonacini M, Fontana RJ, Hayashi PH. Causality assessment in drug-induced liver injury using a structured expert opinion process: comparison to the Roussel-Uclaf causality assessment method. Hepatology. 2010;51(6):2117–26. · DOI · Paper page
  21. Benichou C, Danan G, Flahault A. Causality assessment of adverse reactions to drugs—II. An original model for validation of drug causality assessment methods: case reports with positive rechallenge. J Clin Epidemiol. 1993;46(11):1331–6. · DOI · Paper page
  22. Teschke R, Frenzel C, Wolff A, Eickhoff A, Schulze J. Drug induced liver injury: accuracy of diagnosis in published reports. Ann Hepatol. 2014;13(2):248–55. · DOI · Paper page
  23. Kleiner D, Chalasani NP, Lee WM, Fontana RJ, Bonkovsky HL, Watkins PB, Hayashi PH, Davern TJ, Navarro V, Reddy R, Talwalker TA, Stolz A, Gu J, Barnhart H, Hoofnagle JH. Drug-induced liver injury network (DILIN). Hepatology. 2014;59(2):661–70. · DOI · Paper page
  24. Kim HJ, Lee HW. Important predictor of mortality in patients with end-stage liver disease. Clin Mol Hepatol. 2013;19(2):105–15. · DOI

Cited by

See all 122

Metadata

Authors
Senior, J. R.
Venue
Drug Safety
Published
2014-10-29
Volume
37
Issue
S1
Pages
9-17
ISSN
  • 0114-5916 (ISSN-L)
  • 1179-1942
OpenAlex
W2054603277
Cited by
122
References
3
FWCI
11.92
Type
journal article
Language
en
Open access
hybrid

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Evolution of the Food and Drug Administration Approach to Liver Safety Assessment for New Drugs: Current Status and Challenges. https://app.cochat.ai/papers/10.1007/s40264-014-0182-7
The paper
Senior, J. R. (2014). Evolution of the Food and Drug Administration Approach to Liver Safety Assessment for New Drugs: Current Status and Challenges. Drug Safety. https://doi.org/10.1007/s40264-014-0182-7

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.